Protalix BioTherapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
PLX$2.57+1.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| | |||||||
|---|---|---|---|---|---|---|---|
| | | | | | | | |
| · · · Incorporated by Reference · | |||||||
| Exhibit Number · Exhibit Description · Form · File Number · Exhibit · Date · Filed or Furnished Herewith | |||||||
| 3.1 | | Certificate of Incorporation of the Company | 8-K | 001-33357 | 3.1 | April 1, 2016 | |
| 3.2 | | Amendment to Certificate of Incorporation of the Company | Def 14A | 001-33357 | Appen. A | July 1, 2016 | |
| 3.3 | | Second Amendment to Certificate of Incorporation of the Company | Def 14A | 001-33357 | Appen. A | October 17, 2018 | |
| 3.4 | | Third Amendment to Certificate of Incorporation of the Company | 8-K | 001-33357 | 3.1 | December 19, 2019 | |
| 3.5 | | Fourth Amendment to Certificate of Incorporation of the Company | 10-Q | 001-33357 | 3.5 | August 15, 2022 | |
| 3.6 | | Fifth Amendment to Certificate of Incorporation of the Company | 10-Q | 001-33357 | 3.6 | August 7, 2023 | |
| 3.7 | | Bylaws of the Company | 8-K | 001-33357 | 3.2 | April 1, 2016 | |
| 4.1† | | Form of Restricted Stock Agreement/Notice | 8-K | 001-33357 | 4.1 | July 18, 2012 | |
| 4.2 | | Description of Capital Stock | 10-K | 001-33357 | 4.7 | March 14, 2024 | |
| 4.3 | | Form of Warrant | 8-K | 001-33357 | 4.1 | March 12, 2020 | |
| 4.4† | | Form of Stock Option Agreement (Executives) | 10-Q | 001-33357 | 4.8 | August 10, 2020 | |
| 4.5 | | Form of Stock Option Agreement (Standard) | 10-Q | 001-33357 | 4.9 | August 10, 2020 | |
| 31.1 | | Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | | | | | X |
| 31.2 | | Certification of Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | | | | | X |
| 32.1 | | 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Executive Officer | | | | | X |
| 32.2 | | 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Financial Officer | | | | | X |
| 101.INS | | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document | | | | | X |
| 101.SCH | | Inline XBRL Taxonomy Extension Schema Document | | | | | X |
| 101.CAL | | Inline XBRL Taxonomy Extension Calculation Linkbase Document | | | | | X |
| 101.DEF | | Inline XBRL Taxonomy Extension Definition Linkbase Document | | | | | X |
| 101.LAB | | Inline XBRL Taxonomy Extension Labels Linkbase Document | | | | | X |
| 101.PRE | | Inline XBRL Taxonomy Extension Presentation Linkbase Document | | | | | X |
| 104 | | COVER PAGE INTERACTIVE DATA FILE (formatted as Inline XBRL and contained in Exhibit 101). | | | | | |
| † Management contracts or compensation plans or arrangements in which directors or executive officers are eligible to participate. | |||||||
|---|---|---|---|---|---|---|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.